Relevant studies have confirmed that PPARγ activation improved myocardial cell injury caused by ischemia/reperfusion (Zhou et al., 2017), reduced myocardial fibrosis (Ma et al., 2017), reduced cardiomyocyte apoptosis, and inhibited cardiac hypertrophy (Peng et al., 2017). The gene discussed is PPARG; the disease is Myocardial fibrosis.